Sight Sciences (SGHT) Q3 2025: TierCare Medicare Coverage Unlocks 10.4M Lives, Setting Stage for Interventional Dry Eye Growth
Sight Sciences’ third quarter marked a pivotal moment as TierCare, the company’s interventional dry eye platform, secured Medicare fee schedules covering 10.4 million lives, signaling a new reimbursed category in ophthalmology. Surgical glaucoma momentum continued, with Omni adoption driving sequential and year-over-year gains even amid ongoing tariff headwinds. The company’s sharpened focus on commercial execution and cost discipline, paired with expanded coverage, positions both core franchises for renewed growth into 2026.
Summary
- TierCare Market Access Milestone: Medicare pricing for TierCare now covers over 10 million lives, catalyzing provider engagement.
- Surgical Glaucoma Resilience: Omni platform gains share despite industry headwinds and tariff cost drag.
- 2026 Growth Setup: Expanded reimbursement and leaner cost base support dual-segment acceleration next year.
Performance Analysis
Sight Sciences delivered a mixed but strategically consequential third quarter as it advanced its dual-pronged approach in glaucoma and dry eye disease interventions. Surgical glaucoma, the company’s largest business, returned to growth with revenue up year-over-year and sequentially, driven by increased adoption of the Omni platform and record ordering accounts. Average selling prices rose due to higher OmniEdge utilization, though utilization per account remained flat, and tariff-related costs continued to weigh on gross margins.
The dry eye segment saw a sharp revenue decline as Sight Sciences intentionally slowed SmartLid sales to focus on TierCare’s reimbursement breakthrough. The recent establishment of Medicare fee schedules by Novitas and First Coast for CPT code 0563T, retroactive to January 1, 2025, marks a foundational shift: TierCare procedures are now reimbursed at $1,142 per treatment for 10.4 million Medicare beneficiaries. This milestone, coupled with an existing installed base of 200 providers in covered states, has already sparked heightened customer engagement and sets the stage for a ramp in utilization as payer coverage expands.
- Glaucoma Ordering Accounts Hit Record: Both reactivated and new accounts contributed, up 2% sequentially and 8% year-over-year.
- Gross Margin Resilience Amid Tariffs: Company-level gross margin improved to 86%, though surgical glaucoma margins were flat due to $0.4 million in tariff costs.
- Cost Discipline Sharpens: Adjusted operating expenses fell 17%, reflecting restructuring and focused investment in growth levers.
Cash burn moderated, with $92.4 million in cash and $40 million debt at quarter-end, providing runway for commercial execution as both segments prepare for renewed growth in 2026.
Executive Commentary
"With two clinically proven, efficacious, and reimbursed interventional technologies for these two major anterior segment diseases, we believe that we have a unique opportunity across functionally leveraged team, market, and disease synergies to create proprietary value and build a leading interventional eye care company."
Paul Badawi, Co-Founder & Chief Executive Officer
"We are also reducing our adjusted operating expense guidance for full year 2025 to 90 to 92 million, representing a decrease of 9% to 11% compared to 2024. This guidance still includes investments in pseudophagic standalone market development, tier care market access and commercialization, as well as focused research and development projects, and also reflects reductions in spend associated with the August reduction in force."
Jim Rodberg, Chief Financial Officer
Strategic Positioning
1. TierCare: Pioneering Reimbursed Interventional Dry Eye
TierCare, the company’s in-office interventional dry eye procedure, is now formally reimbursed in two major Medicare Administrative Contractor (MAC) regions, unlocking access for 10.4 million Medicare lives. The $1,142 per-procedure fee schedule validates clinical and economic value, and the company is leveraging an installed base of 200 providers in these states to accelerate adoption. Early claims have already been successfully processed, confirming payment flows and catalyzing provider reengagement. Management is prioritizing commercial resources to drive density in covered geographies and expand payer coverage, with commercial and Medicare Advantage plans as next targets.
2. Surgical Glaucoma: Omni Platform Anchors Share
Omni, Sight Sciences’ flagship surgical glaucoma system, continues to serve as a foundational therapy as the market adapts to new restrictions on multiple MIGS (minimally invasive glaucoma surgery) procedures per cataract surgery. The company’s tenured salesforce has maintained surgeon relationships, reactivated dormant accounts, and expanded utilization of the higher-ASP OmniEdge variant. UnitedHealthcare’s expanded coverage, effective October 2025, is expected to further drive growth in the coming quarters. The company is also targeting the standalone pseudophakic segment, where Omni can be used outside of cataract settings, to expand its addressable market.
3. Commercial Execution and Cost Restructuring
Sight Sciences enacted a reduction in force and realigned spending, resulting in a 17% drop in adjusted operating expenses and a projected $12 million in annualized personnel savings. The company has protected sales and R&D investment while trimming general and administrative costs, aiming for scalable growth. Manufacturing diversification outside of China is underway to mitigate tariff risk, with new facilities expected to begin production in early 2026.
4. Pipeline and Market Development
With a record of clinical validation (e.g., the Sahara study for TierCare), the company is investing in further evidence generation and education to support broader adoption and payer engagement. Market development efforts are focused on engaging the estimated 6,500 U.S. eye care providers with high dry eye procedure potential, leveraging both existing and new customer relationships.
Key Considerations
This quarter’s results reflect a strategic inflection as Sight Sciences transitions from reimbursement uncertainty to commercial execution in both core markets. The company’s ability to translate payer wins into sustained utilization and revenue growth will be the key determinant of long-term value creation.
Key Considerations:
- TierCare Adoption Curve: Will provider activation and patient throughput ramp quickly now that reimbursement is established, or will payer expansion be needed for step-change growth?
- Omni Share Gains: Can Sight Sciences further consolidate share as competitors reposition and the MIGS market returns to growth in 2026?
- Tariff and Manufacturing Risk: Execution on manufacturing relocation is critical to margin stability as tariffs remain a persistent cost headwind.
- Expense Leverage: Sustaining cost discipline while investing in market development and sales expansion will test organizational agility.
Risks
Key risks include the pace and breadth of additional payer coverage for TierCare, potential delays or execution challenges in manufacturing relocation, and ongoing exposure to tariffs on products sourced from China. Competitive dynamics in both the dry eye and glaucoma markets remain fluid, with the risk of pricing pressure or slower-than-expected provider adoption. Regulatory or reimbursement setbacks could also impact momentum.
Forward Outlook
For Q4 2025, Sight Sciences guided to:
- Revenue of $76 to $78 million for full year 2025 (up from prior $72 to $76 million), with dry eye segment contributing $0.5 to $1 million in Q4.
- Adjusted operating expenses of $90 to $92 million for the full year, reflecting ongoing cost discipline and targeted investment in growth initiatives.
Management highlighted:
- Continued investment in TierCare market access, commercialization, and clinical evidence generation.
- Anticipated return to growth in both glaucoma and dry eye segments in 2026 as coverage and utilization expand.
Takeaways
Sight Sciences is at a commercial turning point as TierCare secures foundational reimbursement, setting up a new revenue stream with high recurring potential. The Omni platform’s resilience in surgical glaucoma, paired with a leaner cost structure, provides a stable base for dual-segment growth. Investors should monitor the cadence of new payer wins and the ramp in TierCare procedures as leading indicators of the company’s ability to leverage its first-mover advantage.
- TierCare’s reimbursement win is a structural catalyst, but execution on provider activation and payer expansion will determine the speed of revenue realization.
- Omni’s entrenched position and expanding coverage offer a reliable growth anchor as the MIGS market recovers.
- 2026 will be a proving year for the company’s ability to translate market access into commercial scale across both platforms.
Conclusion
Sight Sciences’ Q3 2025 results mark a strategic inflection, with TierCare’s Medicare coverage unlocking a new reimbursed category and Omni’s commercial momentum reinforcing the company’s dual-platform leadership. Sustained execution on market development, payer engagement, and cost discipline will be essential as the company enters a critical growth phase in 2026.
Industry Read-Through
Sight Sciences’ success in establishing Medicare reimbursement for an in-office interventional dry eye procedure signals a broader shift toward procedural solutions in ophthalmology, with payers increasingly open to covering clinically validated, cost-effective alternatives to chronic pharmacologic management. Competitors in both glaucoma and dry eye segments will face heightened pressure to deliver clinical and economic value, while device manufacturers across medtech should note the importance of payer engagement and health economic data in unlocking new TAMs. Manufacturing localization and tariff mitigation remain industry-wide imperatives as global supply chains face ongoing policy and cost volatility.